About the Product

Description


Dozyfyle S Tablet containing Doxofylline and Salbutamol is used for the management of asthma, bronchospasm, and other respiratory conditions associated with breathing difficulty. It helps improve airflow and respiratory comfort.

Doxofylline works as a bronchodilator that relaxes airway muscles, while Salbutamol helps open narrowed air passages and supports easier breathing.

The tablet is widely prescribed in respiratory and pulmonary care practice for chronic airway disorders, leading to consistent prescription demand.

With increasing prevalence of asthma and respiratory disorders, this product offers strong business potential for retailers and distributors. Its dual bronchodilator action, broad clinical relevance, and steady market demand make it a reliable product for growth in the respiratory segment.

Some patients may experience tremors, headache, nausea, palpitations, nervousness, or dizziness. Rarely, rapid heartbeat or allergic reactions may occur and require medical attention.

Dozyfyle S Tablet is indicated for asthma, chronic obstructive pulmonary disease (COPD), bronchitis, wheezing, and other respiratory conditions associated with bronchospasm. It helps improve breathing, reduce wheezing, relieve chest tightness, and enhance airflow.

This medicine should be used under medical supervision. Use cautiously in patients with heart disease, high blood pressure, diabetes, or thyroid disorders. Do not exceed the prescribed dose.

Store in a cool, dry place below 25°C, protected from moisture and direct sunlight. Keep the tablets in their original packaging and out of reach of children.

Get in Touch

Regulatory Compliance & Professional Verification

This catalog is a digital representation of the Cafoli Lifecare portfolio and is intended for use by authorized pharmaceutical distributors and PCD franchise partners.

  • No Consumer Sale: We do not entertain retail inquiries or direct sales to patients.
  • Information Accuracy: While we strive for accuracy, product availability, packaging, and regulatory status may change based on CDSCO guidelines and state-specific drug laws.
  • Medical Advice: Patients are strictly advised not to self-medicate or use this information for treatment. Always consult a qualified medical practitioner.
  • Licensing: All business associations are subject to the submission of valid GST and Drug License (DL) documentation.

Frequently Asked Questions

What are the business opportunities for Dozyfyle S Tablet in the PCD pharma franchise market?

Dozyfyle S Tablet, containing Doxofylline 400mg and Salbutamol 2mg, has strong demand in the respiratory and anti-asthmatic segment, making it a valuable product for medical distributors, wholesalers, and pharma franchise partners focusing on chest care and pulmonary disease management portfolios.

Why should medical distributors include Dozyfyle S Tablet in their product range?

Medical distributors and agencies can benefit from the consistent demand for bronchodilator combination therapies used in asthma, COPD, bronchospasm, wheezing, and breathing difficulty. The combination helps improve airway relaxation and breathing capacity, strengthening a comprehensive respiratory care product portfolio.

Does Cafoli LifeCare Pvt Ltd offer PCD pharma franchise opportunities for Dozyfyle S Tablet?

Yes, Cafoli LifeCare Pvt Ltd offers PCD pharma franchise opportunities for Dozyfyle S Tablet with promotional support, monopoly rights, quality packaging, and competitive pricing for distributors and wholesalers.

What benefits do wholesalers get by partnering for Dozyfyle S Tablet distribution?

Wholesalers and medical agencies benefit from strong respiratory prescription demand, seasonal asthma/COPD sales, reliable supply chain support, and good margins when partnering for Dozyfyle S Tablet distribution.

How can I become a distributor or franchise partner for Dozyfyle S Tablet?

Medical distributors, stockists, and wholesalers interested in Dozyfyle S Tablet can contact Cafoli LifeCare Pvt Ltd to discuss franchise opportunities, bulk supply requirements, pricing, and distribution support.